October 2025 – Sequana Medical NV (Euronext Brussels: SEQUA (the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer ...
Late breaking session to feature results from the successful PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback